Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study
18 Years
N/A
Both
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor, Nausea and Vomiting, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cavity Cancer, Small Intestine Cancer
Trial Information
Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study
OBJECTIVES:
- Determine the effectiveness of octreotide in the palliation of bowel obstruction
secondary to cancer.
- Characterize the dose and tolerability of octreotide in this patient population.
OUTLINE: Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5.
Patients who respond well to study may continue octreotide for palliative effects.
PROJECTED ACCRUAL: A total of 9-25 patients will be accrued for this study over 9 months.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Inoperable bowel obstruction secondary to cancer OR
- Metastatic or primary abdominal cancer
- Patient presents with vomiting
- Percutaneous gastrostomy tube allowed
PATIENT CHARACTERISTICS:
Age:
- Over 18
Performance status:
- ECOG 0-4
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
Other:
- No documented hypersensitivity to octreotide
- Not pregnant or nursing
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- Prior chemotherapy allowed
Endocrine therapy:
- Concurrent steroids allowed
Radiotherapy:
- Prior radiotherapy allowed
Surgery:
- Not specified
Type of Study:
Interventional
Study Design:
Primary Purpose: Supportive Care
Principal Investigator
J. Cameron Muir, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Robert H. Lurie Cancer Center
Authority:
United States: Federal Government
Study ID:
NU 97X1
NCT ID:
NCT00004895
Start Date:
October 1999
Completion Date:
October 2002
Related Keywords:
- Colorectal Cancer
- Constipation, Impaction, and Bowel Obstruction
- Extrahepatic Bile Duct Cancer
- Gastric Cancer
- Gastrointestinal Stromal Tumor
- Nausea and Vomiting
- Ovarian Cancer
- Pancreatic Cancer
- Peritoneal Cavity Cancer
- Small Intestine Cancer
- stage I colon cancer
- stage II colon cancer
- stage III colon cancer
- stage IV colon cancer
- stage I gastric cancer
- stage II gastric cancer
- stage III gastric cancer
- stage IV gastric cancer
- recurrent gastric cancer
- stage I pancreatic cancer
- stage II pancreatic cancer
- stage III pancreatic cancer
- stage IV pancreatic cancer
- recurrent pancreatic cancer
- stage I rectal cancer
- stage II rectal cancer
- stage III rectal cancer
- stage IV rectal cancer
- recurrent colon cancer
- recurrent rectal cancer
- stage I ovarian epithelial cancer
- stage II ovarian epithelial cancer
- stage III ovarian epithelial cancer
- stage IV ovarian epithelial cancer
- recurrent ovarian epithelial cancer
- small intestine adenocarcinoma
- small intestine lymphoma
- small intestine leiomyosarcoma
- localized extrahepatic bile duct cancer
- unresectable extrahepatic bile duct cancer
- recurrent extrahepatic bile duct cancer
- recurrent small intestine cancer
- constipation, impaction, and bowel obstruction
- peritoneal cavity cancer
- nausea and vomiting
- gastrointestinal stromal tumor
- Colorectal Neoplasms
- Constipation
- Fecal Impaction
- Intestinal Obstruction
- Stomach Neoplasms
- Nausea
- Vomiting
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Duodenal Neoplasms
- Ileal Neoplasms
- Jejunal Neoplasms
- Bile Duct Neoplasms
- Peritoneal Neoplasms
- Gastrointestinal Stromal Tumors
- Intestinal Neoplasms
Name | Location |
|---|---|
| Robert H. Lurie Comprehensive Cancer Center, Northwestern University | Chicago, Illinois 60611 |
